SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers.

ABSTRACT:

Background

The emergence of immune checkpoint inhibitors (ICIs) is one of the most promising breakthroughs for the treatment of multiple cancer types, but responses vary. Growing evidence points to a link between developmental signaling pathway-related genes and antitumor immunity, but the association between the genomic alterations in these genes and the response to ICIs still needs to be elucidated.

Methods

Clinical data and sequencing data from published studies and our cohort were collected to analyze the association of the mutation status of SMO with the efficacy of ICI therapy in the non-small cell lung cancer (NSCLC) cohort and the pan-cancer cohort. Furthermore, the correlation between SMO mutation and immunotherapeutic biomarkers such as immune cell in

SUBMITTER: Ji W 

PROVIDER: S-EPMC9669061 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature